Browsing by Author Xu, Zusheng
Showing results 1 to 4 of 4
| Issue Date | Title | Author(s) |
| 15-Apr-2023 | The Oral PI3Kd Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial | Wang, Tingyu; Sun, Xiuhua; Qiu, Lihua; Su, Hang; Cao, Junning; Li, Zhiming; Song, Yuqin; Zhang, Li; Li, Dengju; Wu, Huijing; Zhang, Wei; Li, Junmin; Zhou, Keshu; Zhou, Hui; Yang, Yu; Li, Zhifeng; Cen, Hong; Cai, Zhen; Zhang, Zhihui; Fu, Weijun; Jin, Jie; Li, Fei; Wu, Weixin; Gu, Xuekui; Zhu, Weiliang; Liu, Lihong; Li, Zengjun; Yi, Shuhua; Bao, Hanying; Xu, Zusheng; Qiu, Lugui |
| 23-Aug-2021 | Phase 1 clinical trial of the PI3K delta inhibitor YY-20394 in patients with B-cell hematological malignancies | Jiang, Bo; Qi, Junyuan; Song, Yuqin; Li, Zengjun; Tu, Meifeng; Ping, Lingyan; Liu, Zongliang; Bao, Hanying; Xu, Zusheng; Qiu, Lugui |
| 2019 | A phase I study of a selective PI3K delta inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies. | Qiu, Lugui; Qi, Junyuan; Song, Yuqin; Jiang, Bo; Tu, Meifeng; Ping, Lingyan; Li, Zengjun; Zhu, Jun; Xu, Yuanyuan; Bao, Hanying; Xu, Zusheng |
| 2018 | Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3K delta Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies | Qi, Junyuan; Song, Yuqin; Jiang, Bo; Li, Jianyong; Tu, Meifeng; Ping, Lingyan; Li, Zengjun; Xu, Wei; Zhu, Huayuan; Zhu, Jun; Bao, Hanying; Xu, Zusheng; Qiu, Lugui |
